S Yousuf Zafar

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Decision making and quality of life in the treatment of cancer: a review
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 17:117-27. 2009
  2. pmc The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
    S Yousuf Zafar
    Center for Learning Health Care, Duke Clinical Research Institute, Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:381-90. 2013
  3. pmc Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Cancer 119:854-62. 2013
  4. doi request reprint Consensus-based standards for best supportive care in clinical trials in advanced cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Lancet Oncol 13:e77-82. 2012
  5. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
  6. doi request reprint Standards for palliative care delivery in oncology settings
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27701, USA
    Cancer J 16:436-43. 2010
  7. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
  8. doi request reprint Malignancy after solid organ transplantation: an overview
    S Yousuf Zafar
    Divisions of Hematology and Medical Oncology, Duke University Medical Center, 508 Fulton Street 152, Durham, North Carolina 27705, USA
    Oncologist 13:769-78. 2008
  9. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008
  10. pmc A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
    Hope E Uronis
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:271-2. 2013

Detail Information

Publications26

  1. doi request reprint Decision making and quality of life in the treatment of cancer: a review
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 17:117-27. 2009
    ..Although these factors are important, physicians are often unable to effectively judge their patients' preferences. Patients are often unable to fully understand their prognoses and the treatment intent...
  2. pmc The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
    S Yousuf Zafar
    Center for Learning Health Care, Duke Clinical Research Institute, Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:381-90. 2013
    ..Our objective was to describe experiences of insured cancer patients requesting copayment assistance and to describe the impact of health care expenses on well-being and treatment...
  3. pmc Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Cancer 119:854-62. 2013
    ..The objective of this study was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer...
  4. doi request reprint Consensus-based standards for best supportive care in clinical trials in advanced cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Lancet Oncol 13:e77-82. 2012
    ..Availability of resources was cited as a challenge to implementation of best supportive care standards...
  5. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
    ..We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment...
  6. doi request reprint Standards for palliative care delivery in oncology settings
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27701, USA
    Cancer J 16:436-43. 2010
    ..Guideline efficacy has not been evaluated, and their dissemination into standard care has been poor. A conceptual framework for better implementation of existing guidelines might improve usage and outcomes...
  7. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
    ..These data, obtained from a usual-practice setting, provide benchmarks to improve clinical practice...
  8. doi request reprint Malignancy after solid organ transplantation: an overview
    S Yousuf Zafar
    Divisions of Hematology and Medical Oncology, Duke University Medical Center, 508 Fulton Street 152, Durham, North Carolina 27705, USA
    Oncologist 13:769-78. 2008
    ..Treatment involves modification of the immunosuppressive drug regimen, resection of localized disease, and chemotherapy. We present the second reported case of a patient with lung transplantation who developed KS in the lung graft...
  9. pmc Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, USA
    BMC Cancer 8:345. 2008
    ..The objective of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis...
  10. pmc A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
    Hope E Uronis
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:271-2. 2013
    ..We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas...
  11. pmc Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
    John H Strickler
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:251-8. 2012
    ..To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies...
  12. pmc A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
    ..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
  13. pmc Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration
    George L Jackson
    Durham Veterans Affairs Medical Center, Center for Health Services Research in Primary Care, Durham, North Carolina 27705, USA
    J Natl Compr Canc Netw 11:431-41. 2013
    ..NCCN Clinical Practice Guidelines in Oncology were successfully used to develop a measurement system for a VHA research-operations quality improvement partnership...
  14. doi request reprint Electronic patient-reported data capture as a foundation of rapid learning cancer care
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Health System, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Med Care 48:S32-8. 2010
    ....
  15. doi request reprint A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
    Gordana Vlahovic
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:95-102. 2012
    ..This study evaluated the maximum tolerated dose/recommended phase II dose and safety and tolerability of bevacizumab, everolimus and panitumumab drug combination...
  16. pmc Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 4:36-45. 2010
    ....
  17. pmc Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs
    George L Jackson
    Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
    J Clin Oncol 28:3176-81. 2010
    ..We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Comprehensive Cancer Network practice guidelines (six indicators) and timeliness of care (three indicators)...
  18. pmc Longitudinal patterns of chemotherapy use in metastatic colorectal cancer
    S Yousuf Zafar
    Cancer Center Biostatistics Division of Medical Oncology, Department of Medicine and Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC
    J Oncol Pract 5:228-33. 2009
    ....
  19. doi request reprint Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center DUMC, Box 3436, Durham, NC 27710, USA
    Support Care Cancer 17:735-44. 2009
    ..How frequently does care at our institution conform to established guidelines?..
  20. doi request reprint A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Karen E Bullock
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 67:465-74. 2011
    ..This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combination...
  21. ncbi request reprint Use of tablet personal computers for sensitive patient-reported information
    Alexandra Dupont
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Support Oncol 7:91-7. 2009
    ..The e/Tablet electronic system may provide a "safer" environment than paper questionnaires for cancer patients to answer private or highly personal questions on sensitive topics such as sexuality...
  22. doi request reprint Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach
    Amy P Abernethy
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 3:41-9. 2009
    ....
  23. doi request reprint Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    John H Strickler
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA
    Invest New Drugs 32:330-9. 2014
    ..007). Conclusions The RP2D of dasatinib is 70 mg daily in combination with CapeOx/bevacizumab. High levels of srcact expression may predict those patients most likely to benefit from dasatinib. ..
  24. pmc Cancer registration needs assessment at a tertiary medical centre in Kilimanjaro, Tanzania
    Leah L Zullig
    Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    World Health Popul 14:12-23. 2013
    ..For most resources, respondents felt that resources were sufficient or attainable. Respondents were generally confident and committed to registry implementation. Lessons learned at KCMC may be more broadly relevant...
  25. doi request reprint Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy
    Manisha Palta
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    Ann Surg Oncol 19:1535-40. 2012
    ..Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in addition to surgery...
  26. pmc A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Palliat Med 13:1407-13. 2010
    ....